Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Abstract Non-small cell lung cancer (NSCLC) ranks as one of the leading causes of cancer-related deaths worldwide. Despite the prominence and effectiveness of kinase-target therapies in NSCLC treatment, these drugs are suitable for and beneficial to a mere ~30% of NSCLC patients. Consequently, the n...

Full description

Bibliographic Details
Main Authors: Tao Yuan, Chenming Zeng, Jiawei Liu, Chenxi Zhao, Fujing Ge, Yuekang Li, Meijia Qian, Jiamin Du, Weihua Wang, Yonghao Li, Yue Liu, Xiaoyang Dai, Jianya Zhou, Xueqin Chen, Shenglin Ma, Hong Zhu, Qiaojun He, Bo Yang
Format: Article
Language:English
Published: Nature Publishing Group 2024-01-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01706-y

Internet

https://doi.org/10.1038/s41392-023-01706-y

Similar Items